NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
3.210
-0.030 (-0.93%)
At close: Feb 13, 2026, 4:00 PM EST
3.300
+0.090 (2.80%)
After-hours: Feb 13, 2026, 7:21 PM EST
NovaBridge Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
370.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 632.00K | 2.18M | - |
| Dec 31, 2022 | -1.55M | -15.40M | - |
| Dec 31, 2021 | 13.85M | -222.30M | -94.14% |
| Dec 31, 2020 | 236.15M | 231.84M | 5,381.18% |
| Dec 31, 2019 | 4.31M | -3.51M | -44.90% |
| Dec 31, 2018 | 7.82M | 6.04M | 340.20% |
| Dec 31, 2017 | 1.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 216.11M |
| Entrada Therapeutics | 61.52M |
| Autolus Therapeutics | 51.13M |
| Bicycle Therapeutics | 28.34M |
| Aclaris Therapeutics | 15.74M |
| Absci | 2.82M |
| Allogene Therapeutics | 22.00K |
NBP News
- 25 days ago - NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei - GlobeNewsWire
- 5 weeks ago - NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer - GlobeNewsWire
- 6 weeks ago - NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 - GlobeNewsWire
- 2 months ago - NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO - GlobeNewsWire
- 2 months ago - NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO - GlobeNewsWire
- 3 months ago - NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward - GlobeNewsWire
- 3 months ago - NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries - GlobeNewsWire
- 3 months ago - I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform - GlobeNewsWire